通过侧链含有聚合物用于心脏缩治疗的抗体的向输送
Shaodong Zhai1, Nan Hu1, Zhenghao Wang2
1Medical Experimental Center of Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan 030032, China.
Colloids and surfaces. B, Biointerfaces
|November 4, 2025
概括
这项研究开发了一种新型纳米粒子 (PSe@Amd-TAG),以准阿姆洛迪平的输送,用于治疗心脏缩. 通过控制心肌细胞中的水平,纳米粒子有效地改善了心脏功能并减少了纤维化.
科学领域:
- 心血管医学 心血管医学
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 持续的压力会导致病态心脏缩,以纤维化和心肌细胞中过载为标志.
- 过量的会增加活性氧物种 (ROS),恶化纤维化和心脏重塑.
- 阿姆洛迪平是一种通道阻塞剂,已显示出潜在的抗高和抗纤维作用.
研究的目的:
- 开发一种针对性纳米粒子输送系统,用于安洛迪平治疗心肌缩.
- 在心脏缩的小鼠模型中研究含有阿姆洛迪平的纳米粒子 (PSe@Amd-TAG) 的疗效.
主要方法:
- 构建了一种含有的侧链聚合物 (PSe@Amd-TAG),装载有阿姆洛迪平,并使用CREKA进行修改,以便有针对性的输送.
- 评估了PSe@Amd-TAG在横向大动脉收缩 (TAC) 诱导的缩性小鼠中的治疗效果.
- 评估心脏功能,增高标志物 (ANP,BNP,MYH7),心肌细胞大小,纤维化,卡尔莫杜林,细胞内水平以及NFκB信号通路.
主要成果:
- 在TAC小鼠中,PSe@Amd-TAG显著改善了心脏功能.
- 该疗法有效抑制了心肌缩标志物,心肌细胞扩大,心脏纤维化和卡尔莫杜林产生.
- PSe@Amd-TAG显示细胞内水平显著降低,并抑制NFκB信号通路.
结论:
- 新的PSe@Amd-TAG纳米粒子提供了一个有前途的策略,用于针对性地将阿姆洛迪平输送到过度缩的心肌.
- 这种方法有效地抑制过载和NFκB信号传递,为治疗心脏缩提供了一个新的治疗途径.
相关概念视频
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
1.5K
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
909
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
909
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
426
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
426
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
387
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
387